Abrdn Life Sciences Investors (HQL) return on equity (ROE)
Abrdn Life Sciences Investors (HQL) earned a return on equity of 16.7% in fiscal 2025 (the year ended September 30, 2025). That is 1.9 percentage points lower than the 18.6% of fiscal 2024. Figures as of 18 Nov 2026, 12:06 UTC, from Yahoo Finance.
Key facts
- Return on equity, fiscal 2025
- 16.7%
- Change on fiscal 2024
- −1.9 pts
- Highest on record
- 18.6%fiscal 2024
- Lowest on record
- -26.3%fiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Abrdn Life Sciences Investors return on equity (ROE), in more detail
Across the 4 fiscal years on record (2022–2025), the highest was 18.6% in fiscal 2024 and the lowest -26.3% in fiscal 2022. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 5.6%.
Return on equity by fiscal year
Abrdn Life Sciences Investors return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2025 | 16.7% | 1.9 pts down | |
| 2024 | 18.6% | 13.0 pts up | |
| 2023 | 5.6% | 31.8 pts up | |
| 2022 | -26.3% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Abrdn Life Sciences Investors, figure by figure
- Abrdn Life Sciences Investors market cap
- Abrdn Life Sciences Investors revenue
- Abrdn Life Sciences Investors earnings
- Abrdn Life Sciences Investors earnings per share (EPS)
- Abrdn Life Sciences Investors P/E ratio
- Abrdn Life Sciences Investors P/S ratio
- Abrdn Life Sciences Investors P/B ratio
- Abrdn Life Sciences Investors free cash flow
- Abrdn Life Sciences Investors operating margin
- Abrdn Life Sciences Investors dividend
- Abrdn Life Sciences Investors shares outstanding
- Abrdn Life Sciences Investors total debt
- Abrdn Life Sciences Investors cash on hand
- Abrdn Life Sciences Investors total assets
- Abrdn Life Sciences Investors return on invested capital (ROIC)
Abrdn Life Sciences Investors (HQL) overview: price, valuation and scorecard
Abrdn Life Sciences Investors return on equity (ROE): questions and answers
What is Abrdn Life Sciences Investors's return on equity?
Abrdn Life Sciences Investors (HQL) earned a return on equity of 16.7% in fiscal 2025 (the year ended September 30, 2025). That is 1.9 percentage points lower than the 18.6% of fiscal 2024.
Is Abrdn Life Sciences Investors's return on equity high or low compared with its own history?
The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 5.6%.
What are the highest and lowest return on equity figures on record for Abrdn Life Sciences Investors?
Across the 4 fiscal years on record (2022–2025), the highest was 18.6% in fiscal 2024 and the lowest -26.3% in fiscal 2022.
How is Abrdn Life Sciences Investors's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For Abrdn Life Sciences Investors it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Abrdn Life Sciences Investors (HQL) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/HQL/roe
Underlying data: Yahoo Finance.